The 2020 American Society for Radiation Oncology (ASTRO) annual conference was held virtually on Oct 24-28. It is one of the largest international radiation oncology conferences and many oncologists, radiation oncologists, and researchers presented their most current findings. This year, some important clinical trials studying brain metastasis, particularly those combining immunotherapy with radiation therapy, were reported. We have selected the most relevant MBC-related reports from ASTRO 2020 and list them below.
- Practice Update: Addition of Immunotherapy to Radiation Improves Survival in Patients With Brain Metastases Initially Treated Surgically The results of this study suggest that immunotherapy combined with radiation, but not chemotherapy, had improved survival. Further clinical trials may be needed.
- Practice Update: Concurrent Stereotactic Radiosurgery and Immunotherapy is Beneficial for Brain Metastases Timing between stereotactic radiosurgery and immunotherapy may be important for the outcomes of patients with brain mets.
- Practice Update: Stereotactic Radiosurgery Superior to Whole-Brain Radiotherapy for Patients With Numerous Brain Metastases This phase III clinical trial showed that stereotactic radiation is beneficial for patients with more than 4 metastases in the brain.
- Practice Update: Cognition is Worsened More by Whole-brain Radiotherapy (WBR) Than Stereotactic Radiosurgery for Brain Metastases Results from two randomized phase III clinical trials suggest that stereotactic radiation for brain metastases is better than WBR for maintaining the cognition and quality of life of patients.
- Practice Update: Stereotactic Body Radiotherapy Lessens Spinal Pain Due to Metastatic Cancer Better Than Conventional Radiotherapy Results from the CCTG-TROG phase II/III study show that less frequent SBRT is better than conventional radiation for managing spinal pain due to metastasis.